Regeneron's Arthritis Drug Fails COVID-19 Trial
A clinical trial with thousands of hospitalized coronavirus patients failed to hit the mark for the last time on Thursday. A group of COVID-19 patients requiring mechanical ventilation failed to show measurable improvement when treated in a phase 3 trial with Kevzara from Regeneron (NASDAQ: REGN). In June, Regeneron reported Kevzara's failure to provide a benefit for hospitalized COVID-19 patients severe enough to require oxygen, but not severe enough to require mechanical ventilation.
In patients with severe COVID-19 infections, it isn't unusual to see overexcited immune systems do more harm than good. Earlier this year, investigators in China noticed lots of unhelpful immune processes in the lungs initiated by a protein called interleukin-6 (IL-6), and Kevzara seemed like a good fit to address this.
Image source: Getty Images.
Source Fool.com
